https://www.selleckchem.com/products/cddo-im.html
3% vs. 52.8% at year 10; p=0.012). Cessation of NAs after HBeAg seroconversion and long-term consolidation is generally safe and feasible in HBeAg positive CHB patients. Three years of consolidation should be preferred in clinical practice. Cessation of NAs after HBeAg seroconversion and long-term consolidation is generally safe and feasible in HBeAg positive CHB patients. Three years of consolidation should be preferred in clinical practice. According to evidence-based clinical practice guidelines, patients presenting with disabling st
처럼
논평
공유하다
